Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGI-F703EB Cream in Epidermolysis Bullosa
NCT07858422Phase 2Recruiting
- Sponsor
- Energenesis Biomedical Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epidermolysis bullosa (EB) comparing ENERGI-F703EB Cream with Matched vehicle cream (2 arms). Primary endpoint: Incidence of Local Target Lesion Adverse Events. Started Oct 2026; status: recruiting.
02
Drugs
ENERGI-F703EB Cream
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT07858422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07858422.